SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001640334-19-000882
Filing Date
2019-05-15
Accepted
2019-05-15 15:07:12
Documents
44
Period of Report
2019-03-31

Document Format Files

Seq Description Document Type Size
1 FORM 6-K nymx_6k.htm 6-K 8117
2 EX-99.1 nymx_ex991.htm EX-99.1 183558
3 EX-99.2 nymx_ex992.htm EX-99.2 10303
4 EX-99.3 nymx_ex993.htm EX-99.3 10207
11 nymx_ex991img3.jpg GRAPHIC 13501
  Complete submission text file 0001640334-19-000882.txt   1463989

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT nymx-20190331.xml EX-101.INS 212481
6 XBRL TAXONOMY EXTENSION SCHEMA nymx-20190331.xsd EX-101.SCH 50439
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE nymx-20190331_cal.xml EX-101.CAL 28240
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nymx-20190331_def.xml EX-101.DEF 52293
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE nymx-20190331_lab.xml EX-101.LAB 147452
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nymx-20190331_pre.xml EX-101.PRE 113105
Mailing Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2
Business Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2 1-800-936-9669
NYMOX PHARMACEUTICAL CORP (Filer) CIK: 0001018735 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-12033 | Film No.: 19827437
SIC: 2835 In Vitro & In Vivo Diagnostic Substances